MedTrace Logo

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT07229313 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-04-16

No results posted yet for this study

Summary

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Conditions

  • Advance Solid Tumors

Interventions

DRUG

KIVU-107

KIVU-107 will be administered IV.

Sponsors & Collaborators

  • Kivu Bioscience Inc.

    lead INDUSTRY

Principal Investigators

  • Louie Naumovski, MD, PhD · Kivu Bioscience

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-13
Primary Completion
2028-03-31
Completion
2030-03-31
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07229313 on ClinicalTrials.gov